Burzynski: Oh, RATS!!!

After again showing how questionable the “research” of #ScienceBasedMedicine Dr. David H. “Orac” Gorski is:
https://stanislawrajmundburzynski.wordpress.com/2013/07/23/is-dr-david-h-orac-gorski-down-and-out-in-detroit-and-an-ethically-bankrupt-researcher-2/
and he is involved in the “War on Cancer,”(!!!) I decided to provide this more in-depth listing of Burzynski related scientific publications regarding animal, mice, and rat studies re: antineoplastons
——————————————————————
1983 – Burzynski SR, Hendry LB, Mohabbat MO, et al. Purification of structure determination, synthesis and animal toxicity studies of antineoplaston A10. In: Proceedings of the 13th International Congress of Chemotherapy. Vienna, Austria; 1983:17, PS. 12.4 11-4.
——————————————————————
1984 – Burzynski, S.R., Mohabbat MO, Burzynski B.
Animal toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:113-118
——————————————————————
1984 – Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and animal toxicity studies of antineoplaston A2
Drugs Exptl Clin Res 1984;10:607-610
——————————————————————
1985 – Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and acute animal toxicity studies of antineoplaston A2
Future Trends in Chemotherapy 1985;6:481-484
——————————————————————
1986 – Burzynski, S., Mohabbat. M., Lee, S.
Preclinical studies of antineoplaston AS2-1 in mice with oral administration
Drugs Exptl Clin Res 1986;132
——————————————————————
1986 – Burzynski, S. R., Mohabbat, M. O. , Le e, S. S. Pre clinical studies of antineoplaston AS2-1 and antineoplaston AS2-5
Drugs Exptl Clin Res 1986;12 (suppl1):11-16
http://www.ncbi.nlm.nih.gov/pubmed/3743376/
Drugs Exp Clin Res. 1986;12 Suppl 1:11-6.
http://www.ncbi.nlm.nih.gov/m/pubmed/3743376/
——————————————————————
1986 – Ashraf, AQ., Liau, M.C., Mohabbat, M.O., Burzynski, S.R.
Preclinical studies of antineoplaston A10 injections.
Drugs Exptl Clin Res 1986;12 (suppl 1):37-45.
http://www.ncbi.nlm.nih.gov/pubmed/3743379/
Drugs Exp Clin Res. 1986;12 Suppl 1:37-45.
http://www.ncbi.nlm.nih.gov/m/pubmed/3743379/
——————————————————————
1986 – Burzynski, S.R., Mohabbat M.O.
Chronic animal toxicity studies on antineoplaston A2.
Drugs Exptl Clin Res 1986;12 (suppl 1):73-75.
http://www.ncbi.nlm.nih.gov/pubmed/3743382/
Drugs Exp Clin Res. 1986;12 Suppl 1:73-5.
http://www.ncbi.nlm.nih.gov/m/pubmed/3743382/
——————————————————————
1987 – Lee, S.S., Mohabbat, M.O., Burzynski, SR
In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3
Drugs Exptl Clin Res 1987;13 (suppl1):13-16
http://www.ncbi.nlm.nih.gov/pubmed/3569011/
Drugs Exp Clin Res. 1987;13 Suppl 1:13-6.
http://www.ncbi.nlm.nih.gov/m/pubmed/3569011/
——————————————————————
1987 – Lee, S.S., Burzynski, S.R
Tissue culture and animal toxicity studies of antineoplaston A5
Drugs Exptl Clin Res 1987;13 (suppl 1):31-5.
http://www.ncbi.nlm.nih.gov/pubmed/3569013/
Drugs Exp Clin Res. 1987;13 Suppl 1:31-5.
http://www.ncbi.nlm.nih.gov/m/pubmed/3569013/
——————————————————————
1987 – Ashraf AQ, Liau MC, Kampalath BN, et al. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exptl Clin Res. 1987;13(suppl 1):45-50.
http://www.ncbi.nlm.nih.gov/pubmed/3569015/
�
http://www.ncbi.nlm.nih.gov/m/pubmed/3569015/
——————————————————————
1988 – Ashraf, AQ., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats
Adv Exptl Clin Chemother 1988;6:33-39
http://www.encognitive.com/node/2449
——————————————————————
7/20/1988 – Chemopreventive effect of antineoplaston A-10 on urethane-induced pulmonary neoplasm in mice
http://www.ncbi.nlm.nih.gov/pubmed/3183462
Nihon Gan Chiryo Gakkai Shi. 1988 Jul.20; 23 (7):1560-5
http://www.ncbi.nlm.nih.gov/m/pubmed/3183462
23(7):1560-5 (1988)
Tsuda
N E
——————————————————————
1/20/1990 – A-10 Injection – The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice
http://www.ncbi.nlm.nih.gov/pubmed/2157780
Nihon Gan Chiryo Gakkai Shi. 1990 Jan 20;25(1):1-5
http://www.ncbi.nlm.nih.gov/m/pubmed/2157780
1st Department of Surgery, Kurume University School of Medicine
The Anticancer Effect of Antineoplaston A-10 on Human Breast Cancer Serially Transplanted to Athymic Mice, Journal of the Japan Society for Cancer Therapy 25(1):1-5 (1990)
Hashimoto K, Koga T, Shintomi Y, Tanaka M, Kakegawa T, Tsuda H, Hara H.
http://www.abstractboard.com/abstract/2157780/The-anticancer-effect-of-antineoplaston-A-10-on-human-breast-cancer-serially-transplanted-to-athymic.html
——————————————————————
1990 – Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. The members of Antineoplaston Study Group
Tsuda H (Japan) et al
http://www.ncbi.nlm.nih.gov/pubmed/2175003
Kurume Med J. 1990;37(2):97-104
http://www.ncbi.nlm.nih.gov/m/pubmed/2175003
Kurume Med J 37 (2):97-104 (1990)
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article
Kurume University School of Medicine, Japan
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article/references
Burzynski References: 1 – 8 and 11 – 14
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_pdf
The Kurume Medical Journal
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://ci.nii.ac.jp/naid/130000888719
——————————————————————
1991 – Inhibitory effect of orally administered antineoplaston A10 on the growth curve of human breast cancer transplanted to athymic mice
http://jglobal.jst.go.jp/public/20090422/200902015871267390
J Jpn Soc Cancer Ther 26:595-601, 1991
26：3：595-601：1991 03
Kurume Univ. School of Medicine
NISHIDA H, YOSHIDA H, KUBOTA H
——————————————————————
5/1992 – The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma
H TSUDA, et al (Japan)
http://www.ncbi.nlm.nih.gov/pubmed/1377669
The Inhibitory Effect of the Combination of Antineoplaston A-10 Injection with a Small Dose of cis-Diamminedichloroplatinum on Cell and Tumor Growth of Human Hepatocellular Carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/1377669
Jpn J Cancer Res. 1992 May;83(5):527-31
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract
Jpn. J. Cancer Res. 83, 527-531
http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf?v=1&t=hd97ht7z&s=3481466c7830e5f8e2bb925a698de6f8155da747
Jpn J Cancer Res. 1992 May;83 (5):527-31
http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf;jsessionid=4ECD3F595A3971B5AB87763862867844.d03t02?v=1&t=hbmd55gj&s=a14b626a37db3ecd558109cee30dfe26c71827763862867844
Jpn J Cancer Res 83 (5):527-31 (1992)
http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf?v=1&t=hkfile3i&s=2756f110cf2202084cfc90a3715d8f1f9df7774c
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken
http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf?v=1&t=hdcl29bl&s=dd78f02b92e0f5544c136e7b897a7d65bcf5dc71&systemMessage=Wiley+Online+Library+will+be+disrupted+on+23+February+from+10%3A00-12%3A00+BST+%2805%3A00-07%3A00+EDT%29+for+essential+maintenance
Article first published online: 26 AUG 2005
DOI: 10.1111/j.1349-7006.1992.tb01960.x
Japan Journal Cancer Research
Cancer Science, Wiley Online Library
Volume 83, Issue 5, pages 527–531, May 1992
Burzynski References: 1, 4 – 7 and 9
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/references
Nishida (Japan) A-10 Reference: 2
——————————————————————
11/15/1995 – Sodium PHENYLACETATE Induces Growth Inhibition and Bcl-2 Down-Regulation and Apoptosis in MCF7ras Cells in Vitro and in nude mice
http://cancerres.aacrjournals.org/content/55/22/5156.abstract?sid=29b3d08f-4e59-473c-a804-10c68ed99112
Cancer Res. 1995 Nov 15;55(22):5156-60.

Click to access 5156.full.pdf

Institut d’Oncologie Moléculaire et Cellulaire Humaine, Bobigny, France.
http://m.cancerres.aacrjournals.org/content/55/22/5156.full.pdf#page=1
References:
http://m.cancerres.aacrjournals.org/content/55/22/5156
1. SAMID, D., Shac, S., and Sherman, L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992
http://www.naderlibrary.com/burzynski.screen3.htm
——————————————————————
9/2001 – Sodium PHENYLACETATE enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375080
Br J Cancer. 2001 September; 85(6): 917–923.
doi: 10.1054/bjoc.2001.1993
PMCID: PMC2375080
——————————————————————
3/2005 Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat
Hideaki TSUDA
http://www.ncbi.nlm.nih.gov/pubmed/15706406
Oncol Rep. 2005 Mar; 13 (3):389-95
http://www.ncbi.nlm.nih.gov/m/pubmed/15706406
Oncol Rep 13 (3): 389-95 (2005)
http://www.spandidos-publications.com/or/13/3/389
Oncology Reports, 3/2005, Volume 13 Number 3
Pages: 389-395 Oncology Reports, Spandidos Publications
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
——————————————————————
7 – 8/27/2007 Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10
http://www.ncbi.nlm.nih.gov/pubmed/17695534
Induction of Apoptosis in Human Hepatocellular Carcinoma Cells by Synthetic Antineoplaston A10
http://www.ncbi.nlm.nih.gov/m/pubmed/17695534
Anticancer Res. 2007 Jul-Aug;27(4B):2427-31
http://ar.iiarjournals.org/content/27/4B/2427.short
Anticancer Res 27(4B):2427-31 (2007)
http://ar.iiarjournals.org/content/27/4B/2427.long
Anticancer Res. 7 – 8/2007; 27(4B):2427-31

Click to access 2427.full.pdf

Anticancer Research, Vol. 27, No. 4B, 2007, pp. 2427-2431
http://www.iiar-anticancer.org/main.php?pid=3398&id=2&ch=52&gch=&volume=27&issue=4B&show=details&page=2
Anticancer Research
HighWire Press
School of Pharmaceutical Sciences, Shandong University, Jinan, Japan
International Journal of Cancer Treatment
Burzynski References: 1, 3, 5, 13 and 15
Badria (Egypt) A-10 References: 2 and 20
Wang A10 Reference: 4
�
References:
�
Adam L, Crépin M, Savin C, Israël L. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res. 1995 Nov 15;55(22):5156–5160.
�
Shack S, Miller A, Liu L, Prasanna P, Thibault A, SAMID D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin Cancer Res. 1996 May;2(5):865–872.
�
SAMID D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest. 1993 May;91(5):2288–2295.
�
SAMID D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE. Phenylacetate and Phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol. 1997;400A:501–505.
�
SAMID D, Wells M, Greene ME, Shen W, Palmer CN, Thibault A. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res. 2000 Mar;6(3):933–941.
�
Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, SAMID D, et al. A phase I and pharmacokinetic study of intravenous phenylacetate
in patients with cancer. Cancer Res. 1994 Apr 1;54(7):1690–1694.
——————————————————————
3/2005 – Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat.
http://www.ncbi.nlm.nih.gov/pubmed/15706406
Matono K, Ogata Y, Tsuda H, Araki Y, Shirouzu K.
http://www.ncbi.nlm.nih.gov/m/pubmed/15706406
Oncol Rep. 2005 Mar;13(3):389-95
http://www.spandidos-publications.com/or/13/3/389
Oncology Reports
March 2005
Volume 13 Number 3
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
——————————————————————
PUBLICATIONS BY STANISLAW RAJMUND BURZYNSKI AND ASSOCIATES
http://www.cancermed.com
——————————————————————
(former web-site screenshots)

Click to access burzynski_fdauntitled_promo_2012.pdf

——————————————————————
Stanislaw Rajmund Burzynski Publications:

https://stanislawrajmundburzynski.wordpress.com/2013/03/16/stanislaw-rajmund-burzynski-publications/

Advertisement

Is Dr. David H. “Orac” Gorski Down and Out in Detroit and an Ethically Bankrupt Researcher ?

After Gorski’s “research” of Burzynski’s phase I (1) clinical trials:

Critiquing: How Stanislaw Burzynski became Burzynski the Brave Maverick Doctor, part 1:
https://stanislawrajmundburzynski.wordpress.com/2013/07/22/critiquing-how-stanislaw-burzynski-became-burzynski-the-brave-maverick-doctor-part-1/
he asserts:

“For one thing, in 1976 Burzynski had no animal data to speak of”

“In fact, the question of animal studies is an interesting one”

“Both Elias and Jaffe recount a story in which ANPs didn’t work in animal tumors, and Burzynski has been quoted in multiple places as claiming that ANPs are species-specific and that ANPs derived from human blood and urine don’t work in animal tumor models”

“This is in contrast to what Null reports in his near-contemporaneous account, in which he stated that in tissue culture and animal models Burzynski’s ANPs worked “specifically against certain types of cancer,” all with “no toxic side effects”

“It makes one wonder whether the “species specificity” was an excuse developed later to explain the lack of animal data”
� � � � � � � � � � � � � � � � �
National Cancer Institute (NCI) at the National Institutes of Health (NIH)

Laboratory/Animal/Preclinical Studies:
http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page4
“Burzynski states that antineoplaston A is species-specific because it had no therapeutic effect when the human preparation was tested on animal tumor systems”

“Although this finding limits the usefulness of animal model testing, the developer has suggested that a “marked” therapeutic effect was produced in a xenograft bearing human tumor tissue.[1]”

“This claim is made only for antineoplaston A”

“Other formulations of antineoplastons have not been tested in animal models”

Gorski should REALLY read his own blog:
http://scienceblogs.com/insolence/2013/01/21/quoth-joe-mercola-i-love-me-some-burzynski-antineoplastons/
Comment #158 – Didymus Judas Thomas

At the Tu-Quack Center Educate Orac Oracle Phase I

February 4, 2013

.11/15/1982.- 2 Toronto physicians, Martin E. Blackstein, Head of the Division of Oncology at Mount Sinai Hospital & Daniel E. Bergsagel, Chief of Medicine at Princess Margaret Hospital, visited the Burzynski clinic & research institute
.
Both were powerful & respected physicians in the Canadian cancer establishment
.
They returned with a blistering, critical report
.
The essence of their critique was
.
(1) there was little evidence that antineoplastons had significant antitumor activity against human or animal cancers;
.
(2) SRB’s argument that antineoplastons were species-specific created a line of argument for avoiding standard animal & tissue culture screens & required testing in humans
.
SRB cooperated but was dubious
.
There were several test-tube & preventative models in which the drug had showed effectiveness, but the standard NCI pre-screen, P388 mouse leukemia, was not 1 of them. …
.
As he had predicted, these compounds were not effective against mouse leukemia
.
SRB reasonably suggested that NCI try the Antineoplastons in cell-culture assays that were similar to “human solid tumors, especially adenocarcinoma of the breast” …
.
SRB was hardly alone in voicing doubts about the P388 mouse model
.
1983 – Ironically, it was Dr. John Vendetti himself, chief of the NCI’s Drug Evaluation Branch, who coauthored an article in which he argued the limitations of this very mouse system
.
Scientists at NCI had found, for instance, that of 79 drugs which had previously been judged negative in the P388, 14 showed “significant activity” when retested in cell culture assays [1] [2]

Comment #163 – Didymus Judas Thomas

February 4, 2013

Orac’s blog hates links reformatting (www removed)
.
[1] http://www.commonweal.org/pubs/choices/21.html
[2] 9 Moss, The Cancer Ind., 14, 299-300
(Ralph Moss, The Cancer Industry)
�
27. Burzynski SR, Hendry LB, Mohabbat MO, et al. Purification of structure determination, synthesis and animal toxicity studies of antineoplaston A10. In: Proceedings of the 13th International Congress of Chemotherapy. Vienna, Austria; 1983:17, PS. 12.4 11-4.
�
34. Burzynski SR, Mohabbat MO, Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10. Drug Exptl Clin Res. 1984;10:113-118.
�
40. Ashraf AQ, Liau MC, Kampalath BN, et al. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exptl Clin Res. 1987;13(suppl 1):45-50.
http://www.ncbi.nlm.nih.gov/pubmed/3569015/
�
http://www.ncbi.nlm.nih.gov/m/pubmed/3569015/
43. Ashraf AQ, Kampalath BN, Burzynski SR. Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats. Adv Exptl Clin Chemother. 1988;6:33-39.